CG Oncology, Inc. Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- CG Oncology, Inc. price/book ratio for the quarter ending 2026-06-30 was 6.09, a 106.16% increase year-over-year.
- CG Oncology, Inc. price/book ratio for the quarter ending 2026-03-31 was 5.46, a 106.19% increase year-over-year.
- CG Oncology, Inc. price/book ratio for the quarter ending 2025-12-31 was 4.46, a 49.62% increase year-over-year.
- CG Oncology, Inc. price/book ratio for the quarter ending 2025-09-30 was 4.59, a 3.39% decline year-over-year.
- CG Oncology, Inc. price/book ratio for fiscal 2026 was 6.09.
- CG Oncology, Inc. price/book ratio for fiscal 2025 was 4.46, a 49.62% increase from fiscal 2024.
- CG Oncology, Inc. price/book ratio for fiscal 2024 was 2.98.
- Available history
- 2024-03-31 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |